U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06895551) titled 'Methylation Biomarkers for Pioneering Early Esophageal Cancer Detection' on March 19.
Brief Summary: Esophageal cancer is a highly aggressive malignancy with poor prognosis, ranking as the sixth leading cause of cancer-related deaths worldwide, particularly prevalent in regions such as East Asia and East Africa. This prospective multicenter study aims to develop and validate a blood-based DNA methylation model for the early detection of esophageal cancer and high-grade intraepithelial neoplasia (HGIN). The study will enroll 500 patients with malignant lesions, including esophageal cancer and HGIN, and 500 patients with benign lesio...